STEAP4-linked immune changes were examined in myocardial-infarction and lung-cancer comorbidity
Source check: Source checked. Not independent scientific confirmation.
Finding: Integrated patient-data analyses associated STEAP4 with immune dysregulation in myocardial-infarction and non-small-cell lung-cancer comorbidity. Follow-up experiments in a mouse comorbidity model and cell assays examined STEAP4 perturbation; the findings are preclinical and do not establish a human treatment.
Technology: Machine-learning-assisted transcriptomic analysis identified STEAP4; experimental perturbation was assessed in cellular and mouse models.
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
- AI contribution
- Machine-learning-assisted transcriptomic analysis identified STEAP4; experimental perturbation was assessed in cellular and mouse models.
- Test and result
- The study combined transcriptomic analyses with a myocardial-infarction/NSCLC mouse model and cellular assays; STEAP4 perturbation was associated with changes in cardiac function, fibrosis, tumor growth and immune measures.
- Limitation / still unknown
- Bioinformatic and preclinical evidence; no clinical intervention or human therapeutic benefit established.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC13364855/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.